

Bernardo Leon Rapoport

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1249673/bernardo-leon-raपोport-publications-by-year.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

120 papers	5,628 citations	34 h-index	74 g-index
130 ext. papers	6,437 ext. citations	3.8 avg, IF	5.52 L-index

#	Paper	IF	Citations
120	A Case Report of Post-Radiotherapy -Positive Angiosarcoma of the Breast.. <i>Case Reports in Oncology</i> , 2022 , 15, 62-70	1	0
119	Elevated Levels of Soluble CTLA-4, PD-1, PD-L1, LAG-3 and TIM-3 and Systemic Inflammatory Stress as Potential Contributors to Immune Suppression and Generalized Tumorigenesis in a Cohort of South African Xeroderma Pigmentosum Patients.. <i>Frontiers in Oncology</i> , 2022 , 12, 819790	5.3	0
118	Abstract P4-04-11: Dysregulation of immune checkpoint proteins in newly- diagnosed early breast cancer patients. <i>Cancer Research</i> , 2022 , 82, P4-04-11-P4-04-11	10.1	
117	Systemic levels of the soluble co-inhibitory immune checkpoints, CTLA-4, LAG-3, PD-1/PD-L1 and TIM-3 are markedly increased in basal cell carcinoma.. <i>Translational Oncology</i> , 2022 , 19, 101384	4.9	1
116	Tumor-Infiltrating Lymphocytes (TILs) in Early Breast Cancer Patients: High CD3+, CD8+, and Immunoscore Are Associated with a Pathological Complete Response. <i>Cancers</i> , 2022 , 14, 2525	6.6	0
115	A South African Breast Implant-Associated Anaplastic Large Cell Lymphoma: Clinical Presentation and Six-Year Follow-Up. <i>Case Reports in Oncological Medicine</i> , 2022 , 2022, 1-7	0.9	
114	Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management.. <i>International Journal of Womenss Dermatology</i> , 2021 , 7, 625-635	2	3
113	Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer. <i>Frontiers in Pharmacology</i> , 2021 , 12, 743582	5.6	3
112	Supportive care for new cancer therapies. <i>Current Opinion in Oncology</i> , 2021 , 33, 287-294	4.2	2
111	Treatment of infections in cancer patients: an update from the neutropenia, infection and myelosuppression study group of the Multinational Association for Supportive Care in Cancer (MASCC). <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 295-313	3.8	2
110	Dysregulation of soluble immune checkpoint proteins in newly-diagnosed early breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 556-556	2.2	
109	Frontiers in Pharmacology: Review Manuscript Targeting of the Neutrophil as an Adjunctive Strategy in Non-Small Cell Lung Cancer. <i>Frontiers in Pharmacology</i> , 2021 , 12, 676399	5.6	3
108	Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper. <i>Supportive Care in Cancer</i> , 2021 , 29, 1129-1138	3.9	6
107	Analysis of primary endocrine therapy in patients older than 70 years with breast cancer rejecting surgery from a single unit in South Africa including COVID-19 issues. <i>Journal of Geriatric Oncology</i> , 2021 , 12, 1118-1121	3.6	0
106	A Rare Case of Synchronous Waldenström Macroglobulinemia and Cutaneous Squamous Cell Carcinoma with a Lung Mass: A Diagnostic and Management Dilemma. <i>Case Reports in Oncology</i> , 2020 , 13, 1474-1482	1	
105	Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type. <i>BMC Cancer</i> , 2020 , 20, 918	4.8	0
104	High Mobility Group Box 1 in Human Cancer. <i>Cells</i> , 2020 , 9,	7.9	14

103	Contrasting Immunopathogenic and Therapeutic Roles of Granulocyte Colony-Stimulating Factor in Cancer. <i>Pharmaceuticals</i> , 2020 , 13,	5.2	4
102	Prognostic significance of the neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small-cell lung cancer. <i>Lung Cancer Management</i> , 2020 , 9, LMT37	2.6	3
101	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020 , 28, 6119-6128	3.9	6
100	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities. <i>Supportive Care in Cancer</i> , 2020 , 28, 6129-6143	3.9	7
99	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020 , 28, 6159-6173	3.9	3
98	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020 , 28, 6129-6143	3.9	7
97	Cancer immunotherapy-related adverse events: causes and challenges. <i>Supportive Care in Cancer</i> , 2020 , 28, 6111-6117	3.9	9
96	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. <i>Supportive Care in Cancer</i> , 2020 , 28, 6145-6157	3.9	6
95	Role of the Neutrophil in the Pathogenesis of Advanced Cancer and Impaired Responsiveness to Therapy. <i>Molecules</i> , 2020 , 25,	4.8	19
94	Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells. <i>Frontiers in Immunology</i> , 2019 , 10, 2254	8.4	34
93	Meta-analysis comparing incidence of grade 3-4 neutropenia with ALK inhibitors and chemotherapy in patients with non-small-cell lung cancer. <i>Future Oncology</i> , 2019 , 15, 2163-2174	3.6	0
92	Realizing the Clinical Potential of Immunogenic Cell Death in Cancer Chemotherapy and Radiotherapy. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	61
91	Tuberculosis Infection in a Patient Treated With Nivolumab for Non-small Cell Lung Cancer: Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2019 , 9, 659	5.3	24
90	Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice. <i>Frontiers in Oncology</i> , 2018 , 8, 80	5.3	28
89	Neurokinin 1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant. <i>Future Oncology</i> , 2018 , 14, 77-92	3.6	1
88	Infections and Cancer 2018 , 337-348		
87	Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study. <i>BMC Cancer</i> , 2018 , 18, 917	4.8	7
86	Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy. <i>Cancer Medicine</i> , 2018 , 7, 2943	4.8	5

85	Rolapitant for the prevention of delayed nausea and vomiting over initial and repeat courses of emetogenic chemotherapy. <i>Expert Review of Clinical Pharmacology</i> , 2017 , 10, 17-29	3.8	
84	Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and vomiting associated with chemotherapy. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 697-710	4.1	6
83	RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2017 , 17, 585-594.e4	3	25
82	Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting. <i>Cancer Management and Research</i> , 2017 , 9, 41-50	3.6	4
81	Ipilimumab in Pretreated Patients With Advanced Malignant Melanoma: Results of the South African Expanded-Access Program. <i>Journal of Global Oncology</i> , 2017 , 3, 515-523	2.6	2
80	2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. <i>Supportive Care in Cancer</i> , 2017 , 25, 303-308	3.9	46
79	2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents. <i>Supportive Care in Cancer</i> , 2017 , 25, 271-275	3.9	18
78	2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy. <i>Supportive Care in Cancer</i> , 2017 , 25, 289-294	3.9	40
77	2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential. <i>Supportive Care in Cancer</i> , 2017 , 25, 297-301	3.9	7
76	Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy. <i>Supportive Care in Cancer</i> , 2017 , 25, 85-92	3.9	9
75	Delayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current Management. <i>Frontiers in Pharmacology</i> , 2017 , 8, 19	5.6	37
74	Rolapitant: An NK-1 Receptor Antagonist for the Prevention of Chemotherapy- Induced Nausea and Vomiting. <i>Reviews on Recent Clinical Trials</i> , 2017 , 12, 193-201	1.2	2
73	Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations. <i>Drug Design, Development and Therapy</i> , 2017 , 11, 2621-2629	4.4	6
72	Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2016 , 27, v111-v118	10.3	290
71	Rolapitant for the treatment of chemotherapy-induced nausea and vomiting: a review of the clinical evidence. <i>Future Oncology</i> , 2016 , 12, 763-78	3.6	11
70	The Role of Neurokinin-1 Receptor Antagonists in CINV 2016 , 85-105		
69	Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. <i>Annals of Oncology</i> , 2016 , 27, 172-8	10.3	41
68	Current trends in the management of anaemia in solid tumours and haematological malignancies. <i>Current Opinion in Supportive and Palliative Care</i> , 2016 , 10, 189-94	2.6	9

67	The emerging problem of bacterial resistance in cancer patients; proceedings of a workshop held by MASCC "Neutropenia, Infection and Myelosuppression" Study Group during the MASCC annual meeting held in Berlin on 27-29 June 2013. <i>Supportive Care in Cancer</i> , 2016 , 24, 2819-26	3.9	14
66	Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. <i>European Journal of Cancer</i> , 2016 , 57, 23-30	7.5	27
65	2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Annals of Oncology</i> , 2016 , 27, v119-v133	10.3	319
64	A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies. <i>Supportive Care in Cancer</i> , 2015 , 23, 2231-44	3.9	22
63	Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. <i>Oncologist</i> , 2015 , 20, 450-8	5.7	79
62	Sorafenib: a brief review with emphasis on its possible role in breast cancer. <i>Breast Cancer Management</i> , 2015 , 4, 99-110	0.7	
61	Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. <i>Lancet Oncology</i> , 2015 , 16, 1079-1089	21.7	110
60	Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. <i>Lancet Oncology</i> , 2015 , 16, 1071-1079	21.7	106
59	Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). <i>Supportive Care in Cancer</i> , 2015 , 23, 3281-8	3.9	54
58	Impact of rolapitant on quality of life (QoL) in patients (pts) receiving highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9615-9615	2.2	1
57	A phase III, randomized, double-blind study of single-dose intravenous fosaprepitant in preventing chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9629-9629	2.2	2
56	When and how do I use neoadjuvant chemotherapy for breast cancer?. <i>Current Treatment Options in Oncology</i> , 2014 , 15, 86-98	5.4	35
55	Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region. <i>Current Medical Research and Opinion</i> , 2014 , 30, 1875-81	2.5	11
54	Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving highly emetogenic chemotherapy (HEC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9638-9638	2.2	5
53	A phase 3 trial comparing capecitabine in combination with Sorafenib or placebo for treatment of locally advanced or metastatic HER2-Negative breast Cancer (the RESILIENCE study): study protocol for a randomized controlled trial. <i>Trials</i> , 2013 , 14, 228	2.8	29
52	The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia. <i>Supportive Care in Cancer</i> , 2013 , 21, 1793-5	3.9	4
51	Evaluation of circulating soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) to predict risk profile, response to antimicrobial therapy, and development of complications in patients with chemotherapy-associated febrile neutropenia: a pilot study. <i>Annals of Hematology</i> , 2012 , 91, 605-11	3	10
50	Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. <i>International Journal of Dermatology</i> , 2011 , 50, 129-46	1.7	45

49	Management of the cancer patient with infection and neutropenia. <i>Seminars in Oncology</i> , 2011 , 38, 424-30	3.5	14
48	Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement. <i>Supportive Care in Cancer</i> , 2011 , 19 Suppl 1, S1-4	3.9	26
47	Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter?. <i>Supportive Care in Cancer</i> , 2011 , 19, 1001-8	3.9	34
46	Acute emesis: moderately emetogenic chemotherapy. <i>Supportive Care in Cancer</i> , 2011 , 19 Suppl 1, S15-23	3.9	18
45	Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art. <i>Supportive Care in Cancer</i> , 2011 , 19 Suppl 1, S43-7	3.9	66
44	Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecan-based chemotherapy. <i>Supportive Care in Cancer</i> , 2011 , 19, 2063-6	3.9	8
43	Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. <i>Annals of Oncology</i> , 2010 , 21 Suppl 5, v232-43	10.3	502
42	Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. <i>Supportive Care in Cancer</i> , 2010 , 18, 423-31	3.9	191
41	A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. <i>Supportive Care in Cancer</i> , 2010 , 18, 509-22	3.9	129
40	Infections and Cancer 2010 , 195-202		
39	Phase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2009 , 19, 1137-41	3.5	22
38	Completeness in the reporting of dermatologic adverse drug reactions associated with monoclonal antibody epidermal growth factor receptor inhibitors in phase II and III colorectal cancer clinical trials. <i>Clinical Colorectal Cancer</i> , 2008 , 7, 309-14	3.8	13
37	Malaria parasitemia associated with febrile neutropenia in African patients undergoing chemotherapy for haematological malignancies. A report of three patients. <i>Chemotherapy</i> , 2008 , 54, 117-9	3.2	7
36	Bacteraemia in febrile neutropenic cancer patients. <i>International Journal of Antimicrobial Agents</i> , 2007 , 30 Suppl 1, S51-9	14.3	224
35	Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -10. <i>European Journal of Cancer Care</i> , 2007 , 16, 475-83	2.4	50
34	Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599. <i>Journal of Clinical Oncology</i> , 2007 , 25, 418-23	2.2	65
33	Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. <i>Annals of Oncology</i> , 2006 , 17, 20-8	10.3	223
32	Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. <i>Annals of Oncology</i> , 2006 , 17, 614-22	10.3	133

31	Screening and Early Detection of Breast Cancer in Women in Africa and the Middle East 2006 , 71-80		1
30	Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. <i>Supportive Care in Cancer</i> , 2005 , 13, 112-6	3.9	30
29	Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update. <i>Supportive Care in Cancer</i> , 2005 , 13, 80-4	3.9	128
28	Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. <i>Annals of Oncology</i> , 2004 , 15, 743-50	10.3	75
27	Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. <i>BMC Cancer</i> , 2004 , 4, 36	4.8	6
26	First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer: a multicentre phase II study. <i>Breast</i> , 2004 , 13, 219-26	3.6	42
25	Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. <i>Supportive Care in Cancer</i> , 2004 , 12, 555-60	3.9	113
24	The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy. <i>European Journal of Cancer</i> , 2004 , 40, 403-410	7.5	85
23	Is there a possible survival benefit to increasing hemoglobin levels with epoetin alfa during chemotherapy?. <i>European Journal of Cancer, Supplement</i> , 2004 , 2, 20-28	1.6	2
22	Phase II study of pegylated liposomal doxorubicin in patients with metastatic malignant melanoma failing standard chemotherapy treatment. <i>Melanoma Research</i> , 2003 , 13, 201-3	3.3	22
21	Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial. <i>Cancer</i> , 2003 , 97, 40-5	6.4	39
20	Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy. <i>Hematological Oncology</i> , 2003 , 21, 169-80	1.3	40
19	Phase II clinical trial of carboplatin and docetaxel in patients with metastatic ovarian cancer: active combination with low incidence of peripheral neuropathy. <i>International Journal of Gynecological Cancer</i> , 2003 , 13, 287-91	3.5	10
18	Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. <i>Journal of Clinical Oncology</i> , 2003 , 21, 4105-11	2.2	117
17	Malignant pleural mesothelioma: a phase II trial with docetaxel. <i>Annals of Oncology</i> , 2002 , 13, 412-5	10.3	24
16	Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocol. <i>American Journal of Hematology</i> , 2000 , 63, 125-30	7.1	15
15	The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3038-51	2.2	799
14	Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. <i>Journal of Clinical Oncology</i> , 1999 , 17, 1413-24	2.2	450

13	Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs. Standard In-patient care. <i>Chemotherapy</i> , 1999 , 45, 466-76	3.2	20
12	Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: a multicenter, double-masked study. Ondansetron Orally Disintegrating Tablet Emesis Study Group. <i>Clinical Therapeutics</i> , 1999 , 21, 168-173	3.5	31
11	A multicenter, double-blind comparison of i.v. and oral administration of ondansetron plus dexamethasone for acute cisplatin-induced emesis. Ondansetron Acute Emesis Study Group. <i>Anti-Cancer Drugs</i> , 1998 , 9, 593-8	2.4	13
10	Survival determinants in patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 1993 , 50, 215-20	4.9	20
9	Repeated use of granisetron in patients receiving cytostatic agents. <i>Cancer</i> , 1993 , 71, 4043-9	6.4	19
8	Lethal toxic epidermal necrolysis during suramin treatment. <i>European Journal of Cancer</i> , 1992 , 28A, 1294-7	7.5	7
7	Phase II clinical study of pirarubicin in hormone resistant prostate cancer. <i>Investigational New Drugs</i> , 1992 , 10, 119-21	4.3	6
6	Trisomy 5 in Ph+ chronic myeloid leukemia in association with megakaryocytosis. <i>Cancer Genetics and Cytogenetics</i> , 1991 , 51, 273-5		3
5	A phase II clinical study of suramin in combination with mitomycin C in patients with non small cell lung cancer. <i>Lung Cancer</i> , 1991 , 7, 323-328	5.9	4
4	Sister chromatid exchanges in lymphocyte cultures of patients previously treated with dibromodulcitol. <i>Oncology</i> , 1991 , 48, 253-7	3.6	1
3	Plasma melatonin in patients with breast cancer. <i>Oncology</i> , 1990 , 47, 401-5	3.6	22
2	"Idiopathic thrombocytopenic purpura-like syndrome" treated with interferon in a patient with lung cancer. <i>American Journal of Hematology</i> , 1990 , 34, 71-2	7.1	10
1	A Phase II Study of Idarubicin and Prednisone in Multiple Myeloma. <i>Tumori</i> , 1990 , 76, 465-466	1.7	6